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Abstract K-Ras proteins are major drivers of human cancers,
playing a direct causal role in about one million cancer cases/
year. In cancers driven by mutant K-Ras, the protein is locked
in the active, GTP-bound state constitutively, through a defect
in the off-switch mechanism. As such, the mutant protein
resembles the normal K-Ras protein from a structural perspec-
tive, making therapeutic attack extremely challenging. K-Ras
is a member of a large family of related proteins, which share
very similar GDP/GTP-binding domains, making specific
therapies more difficult. Furthermore, Ras proteins lack
pockets to which small molecules can bind with high affinity,
with a few interesting exceptions. However, new insights into
the structure and function of K-Ras proteins reveal opportuni-
ties for intervention that were not appreciated many years ago,
when efforts were launched to develop K-Ras therapies.
Furthermore, K-Ras undergoes post-translational modifica-
tion and interactions with cellular signaling proteins that pres-
ent additional therapeutic opportunities, such as specific bind-
ing to calmodulin and regulation of non-canonical Wnt
signaling.
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Introduction
Activating mutations of signaling molecules occur in many
types of cancer, often at high frequencies [1]. Mutations in
K-Ras alone account for one million deaths/year. In adenocar-
cinoma of the lung, the receptor tyrosine kinase (RTK) path-
way, including Ras, neurofibromin, and Raf kinase, is the
major oncogenic driver pathway, accounting for at least
75 % of all cases. Pancreatic cancer mutations in K-Ras ac-
count for more than 90 % of cases, while mutations in RTKs
themselves are notably absent. Ras genes and other compo-
nents of the Ras/RTK pathway are activated at high frequency
in colorectal cancer, in various hematopoietic malignancies,
and in multiple other cancers, but the contributions from dif-
ferent members of the Ras/RTK pathway vary dramatically,
for reasons that are not understood at all. Notably, the Ras/
RTK pathway is not frequently activated in breast cancers or
prostate cancers, presumably because estrogen and androgen
receptors provide mitogenic stimulation in these tumor types.
However, the degree to which these types of cancer remain
dependent on wild-type Ras proteins has not been clearly
established.
Mutations in the Ras pathway also account for the relative-
ly common syndromes neurofibromatosis type 1 (loss of func-
tion of the Ras GAP neurofibromin) and Noonan’s syndrome
(activating mutations in SHP2, Sos, K-Ras, SPRED1), and
rarer diseases such as Costello syndrome (germline mutations
in H-Ras), cutaneous facial cardio syndrome (activating mu-
tations in B-Raf or MEK) [2]. However, amongst the activat-
ing mutations in the pathway, K-Ras itself is the most fre-
quent, yet it has been the least amenable to drug discovery.
In this review, I will discuss the underlying reasons for this.
The cycle of activation and inactivation
Ras proteins are binary switches: the GTP-bound form is ON,
and the GDP-bound form is OFF [3]. Transition between these
states occurs very slowly in the absence of any signals.
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Transition back from Ras-GDP to Ras-GTP occurs with sim-
ilar kinetics: GDP dissociates from Ras very slowly. Once
GDP has dissociated from Ras, it is replaced by rapid binding
with GTP, which is typically present at a much higher concen-
tration than GDP. These intrinsic properties are probably not
relevant to Ras signaling, since both steps (GTP hydrolysis
and GDP/GTP exchange) are actively regulated by other pro-
teins. Ras proteins accumulate in their GTP states rapidly in
response to signals, through the action of guanine nucleotide
exchange factors (GEFs), of which the best understood is Sos
[4, 5]. This multi-domain protein is recruited to activated re-
ceptors in the plasma membrane. Local proximity to Ras in
the plasmamembrane appears sufficient to activate Ras, based
on the discovery that simply fusing a CAAX motif to the C-
terminal region of Sos renders it constitutively active. Sos is
certainly regulated at many other levels (phosphorylation, for
example, and by allosteric effects of a second Ras binding
site), but membrane translocation seems to be the fundamental
driver.
Similar general principles apply to the Ras inactivation
process, which is mediated by GTP hydrolysis. The intrinsic
rate is very slow, with a t1/2 of hours, but this rate is increased
up to 100,000× by GTPase-activating proteins (GAPs). One
of the better characterized is p120GAP (RASA1): this protein,
like Sos, is recruited to activated receptors and turns Ras off
again through proximity in the plasma membrane.
Neurofibromin is another form of GAP that plays a major role
in regulating Ras in many cell types. This protein exists as a
complex with SPRED proteins that are essential for localiza-
tion of neurofibromin in the plasma membrane [6]. The mech-
anism by which this complex is regulated during signaling is
not yet known. However, of all the Ras GAPs, neurofibromin
is by far the most frequently mutated in human cancer, ac-
counting for about 8 % of lung adenocarcinomas and 25 %
of glioblastomas for example (Cancer Genome Research
Network). In these diseases, loss of neurofibromin most likely
acts as a primary driver, pheno-copying activating mutations
in Ras which generally function through rendering Ras pro-
teins insensitive to GAP action [7].
What Ras proteins do
Genetic analysis of Ras function in model organisms helped
enormously to delineate the Ras pathway. In Caenorhabditis
elegans and Drosophila melanogaster, Ras activates the
MAPK pathway (Fig. 1a). The same pathway exists in mam-
malian cells, though many details need to be resolved. For
example, the precise roles of KSR and SHP2 are still unclear
at the molecular level, and we still do not understand exactly
how Ras proteins activate Raf kinase, an essential step in the
Ras signaling pathway. In normal mammalian cells, and in
many cancers, the Raf/MAPK pathway is indeed the major
effector pathway. For example, in mouse embryonic fibro-
blasts (MEFs) devoid of Ras proteins, proliferation and mi-
gration can be rescued by activated alleles of Raf, MEK or
ERK, but not by other candidate effectors, PI3K or RalGDS
[8]. Furthermore, tumors driven by K-Ras in mouse models
can be ablated by deletion of c-Raf [9]. However, it has been
clear for many years that alternative effector pathways may
exist: for example, in Saccharomyces cerevisiae, Ras proteins
perform very different functions: they regulate adenylyl cy-
clase activity. In Dictyostelium discoideum, Ras proteins di-
rectly regulate PI3K and mTOR and do not control theMAPK
pathway. In Schizosaccharomyces pombe, Ras proteins do
activate a MAPK pathway, but the direct effector of Ras is a
kinase that does not resemble Raf kinase at all-in overall do-
main structure and organization [10].
Mammalian Ras proteins in their GTP state bind and acti-
vate several other effectors in addition to Raf kinases, each of
which has been shown to play a role in Ras-driven cancers.
Class I PI3K bind to Ras.GTP directly [11], resulting in in-
creased activity. Furthermore, this interaction is necessary for
tumor formation and maintenance in mouse models of K-Ras
lung cancers [12, 13] as well as induction of angiogenesis
[14]. However, some types of cancer driven by Ras oncogenes
do not appear to utilize this mechanism to activate PI3K, and
more work needs to be done to determine the molecular pa-
rameters that govern this interaction. One interesting approach
that supports a critical role for PI3 kinase activation in Ras
carcinogenesis utilized Ras mutants that are defective in PI3K
binding. These mutants are defective at tumor initiation in
mouse lymphoma models: however, tumors that do emerge
show elevated levels of PI3K signaling, often through loss of
expression of PTEN. They seem to compensate for loss of Ras
activation of PI3K by this alternative mechanism [15].
RalGDS proteins (RalGDS, RGL, RGL2, and RGL3) are also
well-validated effectors of Ras signaling, though their precise
role is less clear [16]. The roles of distinct Ras effectors in
normal cells and in cancer have been discussed recently else-
where [17, 18].
The target itself
The Ras protein consists of a highly conserved G-domain and
a hypervariable tail that is involved in membrane localization
and, in some cases, unique functions that distinguish Ras iso-
forms [17]. The first 80 amino acids of the G-domain are
identical between H-Ras, K-Ras, and N-Ras and contain the
two regions of the Ras protein that undergo major conforma-
tional changes between the GDP-bound form and the GTP-
bound form. These two regions, switch one and switch two,
are the sites of binding of Ras’ effectors and GAPs. Raf ki-
nases bind at amino acids 32–40 within switch one, PI3K,
RalGDS and GAPs bind at both switches one and two
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(Fig. 1b). These 80 amino acids are also highly conserved
between proteins of the Rap family, and proteins of the R-
Ras family [19]. This is relevant to drug discovery, as these
Ras relatives perform distinct functions in cell biology that
appear unrelated to effector functions of the H, N, and K-
Ras. For example, Rap proteins regulate multiple processes
linked to actin cytoskeletal dynamics, including integrin-
mediated and cadherin-mediated adhesion, all functions that
are distinct from those ascribed to Ras. Rap proteins do not
activate Raf kinase in vivo, even though their effector binding
Fig. 1 a The Ras MAP kinase pathway. b The K-Ras 4B protein
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regions (amino acids 32–40) are identical to Ras. Indeed, Rap
proteins bind Raf kinase in vitro, but fail to do so in vivo, for
reasons that are not understood. Nevertheless, the possibility
that drugs that bind to the Ras G-domain may also bind G-
domains of Ras family members needs to be taken seriously.
The G-domain binds guanine nucleotide with picomolar
affinity. These nucleotides hold the Ras protein in active or
inactive states, and only cycle on and off Ras in response to
signals. For this reason, the approach of blocking Ras with
nucleotide competitors seems extremely challenging.
Furthermore, cellular pools of GTP approach millimolar con-
centrations, further complicating attempts to utilize GTP or
GDP competitive analogs. The high degree of conservation
between members of the Ras superfamily presents another
complication to this approach. While these parameters appear
daunting, there may yet be opportunities to exploit nucleotide
binding properties of Ras proteins therapeutically. For exam-
ple, when Sos binds Ras, the off-rate for GDP increases dra-
matically, allowing exchange of GDP for GTP, which exists at
a sufficiently high concentration to bind Ras even during this
low affinity state. This might present an opportunity for com-
petitive binding of a nucleotide analog that somehow inhibits
function.
Mutations in the GTPase site prevent GAP-mediated GTP
hydrolysis and reduce intrinsic GTPase activity: they also
present a unique opportunity for therapeutic intervention.
The G12Cmutation has been targeted directly by electrophilic
compounds that bind in a pocket close to G12C, or to the
GTP-site itself, and covalently bind to the cysteine residue
[20, 21]. These compounds lock the Ras protein in its inactive
GDP state and so prevent downstream signaling. Whether
similar strategies can be employed to target other mutations
remains to be seen. G12D is the most common allele, but the
aspartate side group offers fewer chemical options for reactive
attack.
Analysis of Ras structures using NMR and molecular dy-
namic modeling has led to recognition that the G-domain ac-
tually exists as two lobes [22]. The first, which consists of
amino acids 1–86, contains the effector binding regions
switches one and two, as well as the P-loop (10–17). This lobe
is identical between H-Ras, N-Ras, and K-Ras, as described
above. The second lobe diverges slightly between isoforms
and has been referred to as the allosteric lobe. This lobe is
predicted to form direct contacts with the plasma membrane
and contains sites of potential allosteric regulation by ligands
such as acetate and calcium [22]. Binding of these ligands
causes conformational changes which affect the conformation
of switch two in the first lobe, and could therefore have an
important role in signaling. These exciting discoveries suggest
new possibilities for identifying small molecules that affect
Ras activity.
The most direct and obvious way to attack oncogenic Ras
would be to restore GAP-mediated GTP hydrolysis. This
would address the primary cause of oncogenic activation.
This approach seems, at first sight, to be technically out of
reach, as it would require precise re-structuring of the active
site, to allow the optimal orientation of the arginine finger
from GAP, water molecules in the active site, the gamma
phosphate of GTP and side chains of glutamine, and possibly
other Ras residues. Furthermore, there may be little space in
the active site for a small molecule to bind. However, no
structures have been solved of oncogenic Ras mutants com-
plexed with GAPs. Therefore, the possibility of affecting the
GTPase activity of this complex should not be dismissed too
quickly. Furthermore, intrinsic GTPase might be important in
regulating the duration of Ras signaling, so that modest
increases in this parameter could have useful therapeutic
benefit [17].
Post-translational modifications
The C-terminal CAAX motif is modified in three steps:
farnesylation, proteolysis, and esterification of the C-
terminal carboxylic acid (Fig. 1b). Fully processed Ras
proteins derive specificity and high affinity for plasma
membranes through subsequent palmitoylation (H-Ras,
N-Ras, K-Ras 4A) or through association of lysine residues
with membrane lipids (K-Ras4B). Membrane association
is essential for Ras function: therefore, enzymes involved
in Ras processing have long been evaluated as therapeutic
targets [23]. Unfortunately, targeting farnesyl transferase
was unsuccessful, most likely because geranylgeranyl
transferase can also modify K-Ras and N-Ras proteins in
the absence of farnesyl transferase activity. H-Ras proteins
are not substrates for this back-up mechanism, and new
efforts are underway to test farnesyl transferases in cancers
driven by mutant H-Ras. The other enzymes involved in
Ras processing, the Ras CAAX endopeptidase RCE1 and
the isoprenylcysteine carboxy methyltransferase (ICMT)
and palmitoyl transferases, have not been fully validated
as suitable drug targets, because these enzymes are in-
volved in processing multiple other proteins, or because
data from knock-out experiments have produced conflict-
ing results. However, we should not exclude the possibility
that new insights into Ras processing and new chemical
approaches might restore interest in targeting Ras process-
ing, as discussed in Cox et al. [23].
A novel aspect of Ras signaling has been exploited
recently as a new therapeutic strategy. This is based on
new insights in intramembrane trafficking and the appre-
ciation that plasma membranes are constantly in the pro-
cess of re-cycling. Chaperone proteins are therefore re-
quired to maintain Ras proteins at the plasma membrane.
PDE-delta is a farnesyl-binding protein that performs this
function for K-Ras 4B and other farnesylated proteins.
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Inhibition of the interaction between K-Ras 4B and PDE-
delta inhibits K-Ras 4B function and suggests new ave-
nues for therapy [24].
In addition to the well-studied processing reactions at
the CAAX box at the C-terminus, and at sites of
palmitoylation (N-Ras, H-Ras, K-Ras 4A), Ras proteins
can be modified by acetylation [25], ubiquitination [26],
or, in the case of K-Ras 4B, by phosphorylation [27].
While the importance of the former modifications has been
difficult to assess, the role of phosphorylation is becoming
more clear. PKC promotes phosphorylation of S-181 on K-
Ras 4B, resulting in an electrostatic switch that affects K-
Ras 4B association with the plasma membrane and compro-
mises K-Ras 4B’s activity [27, 28]. In addition, phosphory-
lation prevents association of K-Ras 4B with calmodulin
[29]. As a result, CaM kinase activity is decreased, resulting
in loss of signaling through the non-canonical Wnt/Ca2+
signaling pathway [30]. This promotes cancer cell stem-ness,
as defined by tumor initiating potential, though the mecha-
nism by which this is achieved is not yet clear. Agents that
increase PKC activity and K-Ras 4B phosphorylation, such
as bryostatin [27] or prostratin [30], interfere with K-Ras 4B
signaling and prevent K-Ras-induced stem-ness and so pre-
vent tumor initiation, in several mouse models of cancer.
These data offer a novel approach to cancer therapy that is
mediated by direct effects on K-Ras, albeit through path-
ways that appear unrelated to the traditional effector path-
ways shown in Fig. 1a.
Conclusions
The challenge of targeting Ras onco-proteins effectively and
safely is certainly enormous. However, the urgent clinical
need is also enormous and clearly justifies renewed efforts
to tackle this extremely difficult problem. The biochemical
properties of the protein, including its high affinity for nucle-
otide and lack of druggable pockets, are part of the problem.
Further difficulties, along with the subtle nature of the activat-
ing mutations, are the very high degree of similarity with other
Ras proteins and Ras’ cousins. However, progress is being
made through clever insights into new chemical approaches
and a better understanding of biophysical properties of the
protein and a new appreciation of the roles of post-
translational modifications. This new momentum leads us to
be cautiously optimistic. In parallel, other approaches to si-
lence expression of Ras genes, new ways of identifying down-
stream vulnerabilities, and the possibility of harnessing the
immune system to attack mutant Ras proteins directly, or
Ras cancers indirectly, all add to the sense that this problem
will be solved and that finally patients suffering from Ras-
driven cancers will benefit from revolution in cancer drug
discovery and treatment that has already affected countless
cancer patients whose tumors are driven by more refractory
targets.
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